Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Moderna, Inc. stock logo
MRNA
Moderna
$30.47
+0.6%
$26.65
$23.15
$129.39
$11.78B1.848.69 million shs6.97 million shs
Novavax, Inc. stock logo
NVAX
Novavax
$6.80
+0.5%
$6.76
$5.01
$17.81
$1.10B2.696.30 million shs2.29 million shs
Ocugen, Inc. stock logo
OCGN
Ocugen
$0.97
+4.3%
$0.90
$0.52
$1.98
$282.10M4.184.60 million shs3.28 million shs
Vaxart, Inc. stock logo
VXRT
Vaxart
$0.43
-1.4%
$0.47
$0.29
$1.07
$98.63M1.142.46 million shs1.62 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Moderna, Inc. stock logo
MRNA
Moderna
+0.63%+10.64%+9.56%+21.35%-73.72%
Novavax, Inc. stock logo
NVAX
Novavax
+0.52%+4.54%-6.40%+8.89%-45.86%
Ocugen, Inc. stock logo
OCGN
Ocugen
+4.27%-6.21%+13.43%+45.92%-41.10%
Vaxart, Inc. stock logo
VXRT
Vaxart
-1.37%-18.87%+2.86%+28.38%-33.05%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Moderna, Inc. stock logo
MRNA
Moderna
4.3889 of 5 stars
4.02.00.04.61.22.50.6
Novavax, Inc. stock logo
NVAX
Novavax
4.5168 of 5 stars
3.12.00.04.71.30.83.1
Ocugen, Inc. stock logo
OCGN
Ocugen
1.033 of 5 stars
3.51.00.00.00.60.00.0
Vaxart, Inc. stock logo
VXRT
Vaxart
2.3028 of 5 stars
3.51.00.00.02.61.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Moderna, Inc. stock logo
MRNA
Moderna
2.04
Hold$46.6152.97% Upside
Novavax, Inc. stock logo
NVAX
Novavax
2.29
Hold$17.00150.18% Upside
Ocugen, Inc. stock logo
OCGN
Ocugen
3.00
Buy$6.00521.12% Upside
Vaxart, Inc. stock logo
VXRT
Vaxart
3.00
Buy$3.00594.44% Upside

Current Analyst Ratings Breakdown

Latest NVAX, MRNA, OCGN, and VXRT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
6/24/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00
6/17/2025
Novavax, Inc. stock logo
NVAX
Novavax
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSell$6.00
6/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform
5/22/2025
Moderna, Inc. stock logo
MRNA
Moderna
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$33.00 ➝ $26.00
5/19/2025
Novavax, Inc. stock logo
NVAX
Novavax
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/12/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
5/12/2025
Ocugen, Inc. stock logo
OCGN
Ocugen
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
5/9/2025
Novavax, Inc. stock logo
NVAX
Novavax
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$78.00 ➝ $70.00
5/2/2025
Moderna, Inc. stock logo
MRNA
Moderna
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$45.00 ➝ $40.00
(Data available from 7/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Moderna, Inc. stock logo
MRNA
Moderna
$3.24B3.64N/AN/A$28.33 per share1.08
Novavax, Inc. stock logo
NVAX
Novavax
$1.21B0.91N/AN/A($3.89) per share-1.75
Ocugen, Inc. stock logo
OCGN
Ocugen
$4.05M69.65N/AN/A$0.10 per share9.66
Vaxart, Inc. stock logo
VXRT
Vaxart
$28.70M3.44N/AN/A$0.26 per share1.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Moderna, Inc. stock logo
MRNA
Moderna
-$3.56B-$8.73N/AN/AN/A-105.67%-28.69%-21.94%7/30/2025 (Estimated)
Novavax, Inc. stock logo
NVAX
Novavax
-$187.50M$2.652.5684.940.0638.14%-115.51%29.99%8/14/2025 (Estimated)
Ocugen, Inc. stock logo
OCGN
Ocugen
-$54.05M-$0.19N/AN/AN/A-1,271.12%-223.00%-92.20%8/6/2025 (Estimated)
Vaxart, Inc. stock logo
VXRT
Vaxart
-$66.95M-$0.27N/AN/AN/A-122.63%-91.89%-38.40%8/14/2025 (Estimated)

Latest NVAX, MRNA, OCGN, and VXRT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Vaxart, Inc. stock logo
VXRT
Vaxart
-$0.07-$0.07N/A-$0.07$2.85 million$20.88 million
5/9/2025Q1 2025
Ocugen, Inc. stock logo
OCGN
Ocugen
-$0.06-$0.05+$0.01-$0.05N/A$1.48 million
5/8/2025Q1 2025
Novavax, Inc. stock logo
NVAX
Novavax
$0.71$2.93+$2.22$2.93$204.08 million$666.66 million
5/1/2025Q1 2025
Moderna, Inc. stock logo
MRNA
Moderna
-$2.92-$2.52+$0.40-$2.52$130.35 million$108.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Moderna, Inc. stock logo
MRNA
Moderna
N/AN/AN/AN/AN/A
Novavax, Inc. stock logo
NVAX
Novavax
N/AN/AN/AN/AN/A
Ocugen, Inc. stock logo
OCGN
Ocugen
N/AN/AN/AN/AN/A
Vaxart, Inc. stock logo
VXRT
Vaxart
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Moderna, Inc. stock logo
MRNA
Moderna
N/A
4.22
4.14
Novavax, Inc. stock logo
NVAX
Novavax
N/A
2.06
2.03
Ocugen, Inc. stock logo
OCGN
Ocugen
1.74
2.60
2.60
Vaxart, Inc. stock logo
VXRT
Vaxart
N/A
0.64
0.64

Institutional Ownership

CompanyInstitutional Ownership
Moderna, Inc. stock logo
MRNA
Moderna
75.33%
Novavax, Inc. stock logo
NVAX
Novavax
53.04%
Ocugen, Inc. stock logo
OCGN
Ocugen
10.27%
Vaxart, Inc. stock logo
VXRT
Vaxart
18.05%

Insider Ownership

CompanyInsider Ownership
Moderna, Inc. stock logo
MRNA
Moderna
11.00%
Novavax, Inc. stock logo
NVAX
Novavax
1.00%
Ocugen, Inc. stock logo
OCGN
Ocugen
4.42%
Vaxart, Inc. stock logo
VXRT
Vaxart
2.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
Moderna, Inc. stock logo
MRNA
Moderna
5,800386.74 million344.20 millionOptionable
Novavax, Inc. stock logo
NVAX
Novavax
1,990161.97 million160.35 millionOptionable
Ocugen, Inc. stock logo
OCGN
Ocugen
80292.03 million279.12 millionOptionable
Vaxart, Inc. stock logo
VXRT
Vaxart
120228.31 million221.69 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Moderna stock logo

Moderna NASDAQ:MRNA

$30.47 +0.19 (+0.63%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$30.50 +0.03 (+0.08%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Novavax stock logo

Novavax NASDAQ:NVAX

$6.80 +0.04 (+0.52%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$6.82 +0.03 (+0.44%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Ocugen stock logo

Ocugen NASDAQ:OCGN

$0.97 +0.04 (+4.27%)
Closing price 07/3/2025 03:55 PM Eastern
Extended Trading
$0.96 -0.01 (-0.93%)
As of 07/3/2025 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Vaxart stock logo

Vaxart NASDAQ:VXRT

$0.43 -0.01 (-1.37%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$0.43 0.00 (-0.46%)
As of 07/3/2025 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.